Charles Schwab Investment Management Inc. Buys 102,860 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Charles Schwab Investment Management Inc. grew its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 5.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,887,994 shares of the biotechnology company’s stock after acquiring an additional 102,860 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.91% of BioCryst Pharmaceuticals worth $14,349,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of BCRX. Deerfield Management Company L.P. Series C boosted its stake in BioCryst Pharmaceuticals by 62.9% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 8,135,804 shares of the biotechnology company’s stock worth $50,279,000 after purchasing an additional 3,140,804 shares in the last quarter. Rice Hall James & Associates LLC lifted its stake in shares of BioCryst Pharmaceuticals by 4.0% in the third quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company’s stock worth $16,444,000 after buying an additional 84,102 shares in the last quarter. Cubist Systematic Strategies LLC lifted its stake in shares of BioCryst Pharmaceuticals by 528.0% in the second quarter. Cubist Systematic Strategies LLC now owns 1,112,232 shares of the biotechnology company’s stock worth $6,874,000 after buying an additional 935,132 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of BioCryst Pharmaceuticals by 12.5% during the second quarter. Bank of New York Mellon Corp now owns 775,957 shares of the biotechnology company’s stock valued at $4,795,000 after buying an additional 86,249 shares during the last quarter. Finally, Panagora Asset Management Inc. increased its position in shares of BioCryst Pharmaceuticals by 2.8% during the second quarter. Panagora Asset Management Inc. now owns 650,318 shares of the biotechnology company’s stock valued at $4,019,000 after acquiring an additional 17,759 shares in the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on BCRX. Needham & Company LLC reaffirmed a “buy” rating and issued a $14.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Barclays upped their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $15.60.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX opened at $7.61 on Monday. The firm has a market capitalization of $1.58 billion, a P/E ratio of -12.48 and a beta of 1.79. BioCryst Pharmaceuticals, Inc. has a one year low of $4.03 and a one year high of $8.88. The business has a fifty day moving average of $7.58 and a 200 day moving average of $7.35.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.07). The firm had revenue of $117.10 million for the quarter, compared to the consensus estimate of $113.99 million. During the same quarter in the prior year, the firm earned ($0.19) earnings per share. The company’s revenue for the quarter was up 35.1% compared to the same quarter last year. Analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current fiscal year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.